March 08, 2019 | Joanne Morrison
Dr. Kathy Neuzil is Leading an International Consortium of Researchers Working to Accelerate Introduction of Typhoid Conjugate Vaccine
Each year there are nearly 11 million cases of typhoid, a disease that is spread through contaminated food, drink and water. Researchers at the University of Maryland School of Medicine are leading an international consortium that is studying the impact of a typhoid conjugate vaccine (TCV) in an effort to accelerate introduction of the vaccine in countries in sub-Saharan Africa and Asia where there is a high burden of typhoid.
In a supplement published by Clinical Infectious Diseases, Kathleen Neuzil, MD, MPH, Professor of Medicine and Pediatrics and Director of the Center for Vaccine Development and Global Health (CVD) at UMSOM, underscores the importance of introducing a TCV, while outlining the challenges in accelerating wide use of the vaccine in typhoid-endemic countries.
“In the past year, policy and financing milestones have paved the way for the introduction TCVs. In this supplement, collaborators from around the globe detail efforts and provide data to inform country-level decisions on vaccine introduction as a critical part of public health interventions to decrease typhoid disease,” said Dr. Neuzil, who is leading the Typhoid Vaccine Acceleration Consortium (TyVAC), an international group of researchers with a mission to accelerate the introduction of TCV in low-income countries.
The special TyVAC journal supplement, edited by Dr. Neuzil, Dr. Andrew Pollard of Oxford University and Dr. Anthony Marfin of PATH, brings together the body of research conducted by TyVAC to date, as well as additional research from other research partners. The research underscores the challenges of typhoid surveillance, the growing resistance to antibiotics and the increasing numbers of typhoid outbreaks in the most vulnerable low-resources settings.
“The growing threat of typhoid necessitates a global effort that includes preventative measures such as vaccines and improved waster, sanitation, and hygiene.,” said Dr. Neuzil.
In the supplement, TyVAC researchers detail clinical trials that are underway in Nepal, Bangladesh, Malawi, and Burkina Faso. They highlight the health economics of the disease, the growing concerns of drug resistance, and the cost-effectiveness of mass campaigns of a vaccine.
Release of the supplement comes as TyVAC researchers in addition to several UMSOM disease experts in the CVD will present their research in Hanoi, Vietnam on March 26-28 at the 11th International Conference on Typhoid and Other Salmonelloses. Dr. Neuzil is a keynote speaker at this event.
“This research led by Dr. Kathleen Neuzil demonstrates the impact our work at the University of Maryland School of Medicine has across the globe. It will help inform global vaccine policymakers in settings where diseases like typhoid are a serious threat,” said UMSOM Dean E. Albert Reece, MD, PhD, MBA, who is also the Executive Vice President for Medical Affairs, University of Maryland, and the John Z. and Akiko K. Bowers Distinguished Professor.
About the University of Maryland School of Medicine
Now in its third century, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world -- with 43 academic departments, centers, institutes, and programs; and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished recipient of the Albert E. Lasker Award in Medical Research. With an operating budget of more than $1 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic and clinically based care for more than 1.2 million patients each year. The School has over 2,500 students, residents, and fellows, and more than $530 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland, Baltimore campus, the School of Medicine has a total workforce of nearly 7,000 individuals. The combined School and Medical System (“University of Maryland Medicine”) has an annual budget of nearly $6 billion and an economic impact more than $15 billion on the state and local community. The School of Medicine faculty, which ranks as the 8th highest among public medical schools in research productivity, is an innovator in translational medicine, with 600 active patents and 24 start-up companies. The School works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit medschool.umaryland.edu.
About the Typhoid Vaccine Acceleration Consortium
The Typhoid Vaccine Acceleration Consortium (TyVAC), a partnership between the Center for Vaccine Development at the University of Maryland School of Medicine, the Oxford Vaccine Group at the University of Oxford, and PATH, an international nonprofit, aims to accelerate the introduction of new typhoid conjugate vaccines (TCVs) as part of an integrated approach to reducing the burden of morbidity and mortality from typhoid in countries eligible for support from Gavi, the Vaccine Alliance (Gavi). It is funded by the Bill & Melinda Gates Foundation.
Contact
Department of Anesthesiology
(410) 328-6120 (phone)
(410) 328-5531 (fax)
newsletter@som.umaryland.edu
Joanne Morrison
Director of Marketing and Public Relations
University of Maryland School of Medicine
jmorrison@som.umaryland.edu
Office: (410) 706-2884
Mobile: (202) 841-3369
Related stories
Tuesday, May 21, 2024
University of Maryland School of Medicine Launches Vaccine Development Program to Prevent Sepsis in Newborns
University of Maryland School of Medicine (UMSOM) researchers at the Center for Vaccine Development and Global Health (CVD) have been awarded up to $3.96 million over three years to develop and test a vaccine in an animal model that could eventually be used in pregnant women to prevent sepsis in newborns and infants.
Monday, July 18, 2022
New Genomic Research Shows Why Testing Malaria Vaccines in the Clinic is as Rigorous as Natural Exposure in the Field
Malaria is the deadliest mosquito-borne parasitic infection of humans. In 2021, after a century of research, the World Health Organization (WHO) approved the world’s first malaria vaccine. That vaccine reduces the incidence of malaria infections in young children aged 5-17 months by only 30 percent, meaning that it remains critical to continue developing and testing more effective vaccines.
Wednesday, January 26, 2022
Trial Co-led by University of Maryland School of Medicine Scientist Confirms Safety of “Mix-and-Match” COVID-19 Vaccine Booster Dosing
A University of Maryland School of Medicine (UMSOM), Center for Vaccine Development and Global Health (CVD), expert is co-leading an ongoing study that was pivotal in recommending adults and teens receive booster COVID-19 shots of their choosing starting in fall 2021. The preliminary clinical trial results, reported today in The New England Journal of Medicine, found that is safe and effective to receive boosters that are the same or a different one from the person’s primary vaccine(s).
Thursday, July 02, 2020
UMSOM Researchers Help Weigh Role of Human Challenge Studies for COVID-19 Vaccine Development
Members of the National Institutes of Health’s (NIH) Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Working Group, which includes Kathleen Neuzil, MD, MPH, DTPH, the Myron M. Levine, MD, DTPH Professor in Vaccinology and Director of the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM), assessed the practical considerations and prerequisites for using controlled human infection models (CHIMs) to support development of a SARS-CoV-2 Vaccine.
Wednesday, October 30, 2019
UM School of Medicine's Myron M. Levine, MD, DTPH, to Receive Prestigious Lifetime Award for Five Decades of Pioneering Vaccine Research
Myron M. Levine, MD, DTPH, the Simon and Bessie Grollman Distinguished Professor at the University of Maryland School of Medicine (UMSOM), Associate Dean for Global Health, Vaccinology and Infectious Diseases, and Founder and Former Director of the Center for Vaccine Development and Global Health (CVD) is a co-recipient of the 2020 Research! America Geoffrey Beene Foundation Builders of Science Award for his pioneering vaccine and infectious disease research.
Monday, October 21, 2019
UM School of Medicine's Kathleen M Neuzil Elected as Member of Prestigious National Academy of Medicine
Kathleen M. Neuzil, MD, MPH, Professor of Medicine and Pediatrics and Director of the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM), has been elected as a member of the National Academy of Medicine (NAM), in recognition of her pivotal research that has informed and shaped global vaccine and public health policy. Her membership was announced at the annual NAM meeting in Washington, D.C., placing her among the 2,178 U.S. members of this important organization. Membership in the Academy is considered one of the highest honors for individuals who have made major contributions to the advancement of the medical sciences, health care and public health.
Friday, September 20, 2019
UM School of Medicine's Center for Vaccine Development and Global Health Receives NIH Contract of up to More than $200 Million for Influenza Research
Kathleen Neuzil, MD, MPH, Professor of Medicine and Pediatrics and Director of the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM) and Dean E. Albert Reece, MD, PhD, MBA, announced that CVD has been awarded a contract from the National Institute of Allergy and Infectious Diseases (NIAID), with total funding up to more than $200 million over seven years if all contract options are exercised.
Monday, August 19, 2019
UM School of Medicine Researcher Warns of Need for Malaria Drug to Treat Severe Cases in U.S.
Each year there are more than 200 million cases of malaria worldwide, a mosquito-borne disease caused by a parasite that brings on fever and body aches and, in some cases, more serious conditions such as coma and death. While the vast majority of these cases occur in sub-Saharan Africa and South Asia, the U.S. each year sees more than 1,500 cases, and currently there is limited access to an intravenously-administered (IV) drug needed for the more serious cases, according to a top malaria researcher at the University of Maryland School Medicine (UMSOM).
Wednesday, July 17, 2019
Vaccines Tested in UM School of Medicine’s Center for Vaccine Development Protect Children Around the World
For 30 years, the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM) has collaborated with the Pediatric Center of Frederick to test vaccines used in pediatric care.
Wednesday, December 26, 2018
Multicenter Trial Supports Use of Topical Antibiotic as a Tool to Eliminate Staph Colonization in NICU Babies
A team of doctors led by Karen L. Kotloff, M.D., University of Maryland School of Medicine (UMSOM), Center for Vaccine Development and Global Health (CVD), has performed a clinical trial involving multiple hospitals that tested the effectiveness of applying a topical antibiotic known as mupirocin for prevention of Staphylococcus aureus (SA) infection in babies in the neonatal intensive care unit (NICU). This study was published in the journal Pediatrics.
Thursday, December 20, 2018
Data From Largest Global Diarrheal Disease Study Available to Scientists on Public Sites
Data collected from the Global Enteric Multicenter Study (GEMS), a multi-site research project studying diarrheal diseases that was designed and coordinated by researchers in the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM), are now available to scientists on two online data resources.
Monday, December 03, 2018
UMSOM and Groupe De Recherche Action En Sante Begin Second Typhoid Conjugate Vaccine Study in Africa
A new study has been launched in Burkina Faso for Bharat Biotech’s typhoid conjugate vaccine (TCV). It is the second clinical study underway in Africa for the vaccine and the first in West Africa. The vaccine study is a joint effort by the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine, (UMSOM) and Groupe de Recherche Action en Santé (GRAS) in Burkina Faso.
Friday, November 02, 2018
UMSOM Global Health Expert Named to Prestigious World Health Organization Immunization Panel
Kathleen Neuzil, MD, MPH, Professor of Medicine and Pediatrics and Director of the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM), has been named to the World Health Organization’s (WHO) Strategic Advisory Group of Experts (SAGE) on Immunization.
Sunday, October 28, 2018
American Society of Tropical Medicine & Hygiene Awards Dr. Miriam Laufer the LePrince Medal for Malaria Research
Miriam Laufer, MD, MPH, Professor of Pediatrics and Associate Director for Malaria Research at the University of Maryland School of Medicine’s (UMSOM) Center for Vaccine Development and Global Health (CVD), was awarded the Joseph Augustin LePrince Medal by the American Society of Tropical Medicine and Hygiene (ASTMH).
Monday, April 23, 2018
UM School of Medicine Launches Newly Organized Center for Vaccine Development and Global Health Under Leadership of International Vaccine Expert Dr. Kathleen Neuzil
University of Maryland School of Medicine (UMSOM) Dean E. Albert Reece, MD, PhD, MBA, announced today the launch of a newly organized Center for Vaccine Development and Global Health (CVD). The new Center will be led by UMSOM Professor of Medicine and Pediatrics, Kathleen Neuzil, MD MPH, FIDSA, one of the world’s most influential research scientists and advocates in vaccine development and policy.
Thursday, September 28, 2017
UM SOM Vaccine Expert Warns of Risks of Influenza to Older Populations
“Protect yourself and others by getting the flu shot” was the message from Kathleen Neuzil, MD, MPH, FIDSA, Director of the Center for Vaccine Development (CVD) at the University of Maryland School of Medicine (UM SOM). Dr. Neuzil was among the speakers at a press conference hosted by the National Foundation for Infectious Diseases. U.S. Secretary of Health and Human Services, Thomas E Price, MD, also spoke at the press conference and urged people to get their flu shot. The panel members all received their flu shots following the press conference.
Monday, May 15, 2017
U.S. CDC Recommends Use of Cholera Vaccine Developed by University of Maryland School of Medicine
A cholera vaccine developed by scientists at the University of Maryland School of Medicine’s Center for Vaccine Development (CVD) has been recommended by the U.S. Centers for Disease Control and Prevention (CDC) for use as a protection for U.S. adults traveling to areas with cholera. The CDC’s latest recommendation was published on May 11, in Morbidity and Mortality Weekly Report.
Thursday, November 10, 2016
International Consortium Receives $36.9 Million Grant to Fight Typhoid
Typhoid fever, a bacterial infection that causes high fever and other disabling symptoms, remains a serious global problem in the developing world: it kills almost a quarter of a million people annually, and infects about 21 million.
Thursday, September 22, 2016
University of Maryland School of Medicine Holds Inaugural Global Health Summit
The Institute for Global Health (IGH) at the University of Maryland School of Medicine (UM SOM) will hold its first Global Health Summit on September 26. The event, which will take place from noon to 6 p.m. in the SMC Campus Center at 621 W. Lombard Street, will seek to foster collaboration among scientists and promote new and innovative global health research at UM SOM, as well as at other schools at the University of Maryland, Baltimore (UMB). Faculty and staff from UM SOM, as well as other schools are welcome at the event.
Thursday, August 04, 2016
UM SOM is Center Stage in Testing National Institutes of Health Zika Vaccine
UM SOM'S Center for Vaccine Development, tapped previously for Ebola vaccine, now steps up to help develop first Zika vaccine.
Wednesday, June 29, 2016
UM SOM Researchers Awarded Grant to Use Innovative Alternative to Autopsies to Better Understand Child Mortality
Kathleen Neuzil, MD, MPH, director of the Center for Vaccine Development (CVD) at the University of Maryland School of Medicine (UM SOM), and UM SOM Dean E. Albert Reece, MD, PhD, MBA, announced today that CVD has been awarded a large grant from the Bill & Melinda Gates Foundation for research that will help determine why so many children under five are dying in the world’s poorest countries. The grant will fund use of an innovative alternative to traditional autopsy known as minimally invasive tissue sampling. The technique, which involves the collection of tissue samples with fine needles, allows researchers to quickly identify the cause of death, and help illuminate ways to save lives and improve the health of children in these vulnerable areas.
Tuesday, April 12, 2016
UM SOM Researcher Dr. Kathleen Neuzil Honored by Vanderbilt University School of Medicine
The Vanderbilt University School of Medicine (VUSM) has announced that Kathleen Neuzil, MD, MPH, director of the Center for Vaccine Development at the University of Maryland School of Medicine (UM SOM), has received the 2016 Vanderbilt University School of Medicine Distinguished Alumni Award.